6090 Stock Overview
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Human Metabolome Technologies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥605.00 |
52 Week High | JP¥777.00 |
52 Week Low | JP¥501.00 |
Beta | 0.58 |
11 Month Change | -4.57% |
3 Month Change | -6.20% |
1 Year Change | -15.27% |
33 Year Change | -22.54% |
5 Year Change | -27.54% |
Change since IPO | -78.71% |
Recent News & Updates
Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market
Aug 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Jun 07Recent updates
Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market
Aug 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Jun 07Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
May 22Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year
Apr 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Mar 23Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00
Feb 26Shareholder Returns
6090 | JP Life Sciences | JP Market | |
---|---|---|---|
7D | 3.8% | 9.6% | 2.9% |
1Y | -15.3% | -33.8% | 14.9% |
Return vs Industry: 6090 exceeded the JP Life Sciences industry which returned -33.8% over the past year.
Return vs Market: 6090 underperformed the JP Market which returned 14.9% over the past year.
Price Volatility
6090 volatility | |
---|---|
6090 Average Weekly Movement | 5.7% |
Life Sciences Industry Average Movement | 8.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in JP Market | 10.1% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 6090 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6090's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 57 | Yasuhiro Ohata | www.humanmetabolome.com |
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma.
Human Metabolome Technologies, Inc. Fundamentals Summary
6090 fundamental statistics | |
---|---|
Market cap | JP¥3.60b |
Earnings (TTM) | JP¥285.00m |
Revenue (TTM) | JP¥1.34b |
12.6x
P/E Ratio2.7x
P/S RatioIs 6090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6090 income statement (TTM) | |
---|---|
Revenue | JP¥1.34b |
Cost of Revenue | JP¥484.00m |
Gross Profit | JP¥855.00m |
Other Expenses | JP¥570.00m |
Earnings | JP¥285.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 48.18 |
Gross Margin | 63.85% |
Net Profit Margin | 21.28% |
Debt/Equity Ratio | 10.4% |
How did 6090 perform over the long term?
See historical performance and comparison